|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
|
30403317 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association between CYP2C19*2/*3 Polymorphisms and Coronary Heart Disease.
|
30868490 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On the contrary, analytical parameters, systemic arterial hypertension, dyslipidemia, smoking or the personal/family history of coronary artery disease did not reach statistical significance regardless of CYP2C19 activity.
|
28473221 |
2017 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.
|
28687336 |
2017 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI).
|
28783717 |
2017 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To compare the clinical effects between individual antiplatelet therapy guided by CYP2C19 genetic testing and conventional dual antiplatelet therapy in patients with coronary artery disease after percutaneous coronary intervention.
|
26727381 |
2016 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the genotype frequencies of cytochrome P450, family2, subfamily C, polypeptide19 (CYP2C19); P2Y12 receptor; and glycoprotein IIIa polymorphisms in patients with coronary heart disease and their impact on clopidogrel responsiveness and major adverse cardiac events (MACEs).A total of 146 coronary heart disease patients of Han ethnicity, on a clopidogrel regimen, were enrolled.
|
27488401 |
2016 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
|
26071277 |
2015 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
|
25891840 |
2015 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients.
|
25823779 |
2015 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
|
25329996 |
2014 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
|
25008027 |
2014 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
|
24608794 |
2014 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
α2A-Adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant.
|
24723553 |
2014 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
|
24535487 |
2014 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
|
24402637 |
2014 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care.
|
23981380 |
2013 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We screened patients with stable coronary artery disease for cytochrome P450 (CYP) 2C19 genotypes and enrolled 103 patients who lacked CYP2C19*2 or *3 loss-of-function allele to minimize the effect of this gene on high RPR.
|
23922147 |
2013 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease.
|
23337798 |
2013 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
|
21693476 |
2012 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Data from six clinical studies demonstrated that carriers of the CYP2C19*17 variant had a marked protection against recurrent cardiovascular events in patients with coronary artery disease compared with non-carriers, as measured by a 16% decrease in the incidence of MACE (10.0% vs. 11.9%; OR, 0.82; 95% CI, 0.72-0.94; P = 0.005).
|
22123356 |
2012 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease.
|
22071359 |
2012 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, carrier status for LOF CYP2C19 is associated with an increased risk of adverse clinical events in patients with coronary artery disease on clopidogrel therapy despite differences in clinical significance according to ethnicity.
|
22591668 |
2012 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Eligibility criteria for selecting studies Original full length reports assessing the cumulative incidence of major adverse cardiovascular events or stent thrombosis over a follow-up period of at least a month in association with carrier status for the loss of function or gain of function CYP2C19 allele in adult patients with coronary artery disease and a clinical presentation of acute coronary syndrome or stable angina pectoris who were taking clopidogrel.
|
21816733 |
2011 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP2C19*2 genotype is associated with an increased risk of definite ST following coronary stent placement among Chinese patients with coronary artery disease receiving clopidogrel.
|
22118006 |
2011 |